The Lymphatic Highway: How Lymphatics Drive Lung Health and Disease

• Published in: Lung Vol. 202; no. 5; pp. 487 - 499
• Main Authors: Zhang, Xinyu, Du, Xinqian, Cui, Ye
• Format: Journal Article
• Language: English
• Published: New York Springer US 01-10-2024; Springer Nature B.V
• Subjects: Abnormalities; Animals; Asthma - physiopathology; Chronic obstructive pulmonary disease; Disorders; Fibrosis; Graft rejection; Graft Rejection - physiopathology; Homeostasis; Humans; Idiopathic Pulmonary Fibrosis - metabolism; Idiopathic Pulmonary Fibrosis - physiopathology; Immune system; Lung - physiopathology; Lung diseases; Lung Diseases - physiopathology; Lung Transplantation; Lymphangiogenesis - physiology; Lymphatic system; Lymphatic System - physiopathology; Lymphatic Vessels - physiopathology; Medicine; Medicine & Public Health; Microenvironments; Pathogenesis; Phenotypes; Pneumology/Respiratory System; Pulmonary Disease, Chronic Obstructive - physiopathology; Respiratory diseases; Review; Structure-function relationships; Edema; Lung diseases; Fibrosis; Immune cell trafficking; Inflammation; Lymphatics; Lymphangiogenesis
• ISSN: 0341-2040; 1432-1750; 1432-1750
• DOI: 10.1007/s00408-024-00739-6

The pulmonary lymphatic system has emerged as a critical regulator of lung homeostasis and a key contributor to the pathogenesis of respiratory diseases. As the primary conduit responsible for maintaining fluid balance and facilitating immune cell trafficking, the integrity of lymphatic vessels is essential for preserving normal pulmonary structure and function. Lymphatic abnormalities manifest across a broad spectrum of pulmonary disorders, underscoring their significance in respiratory health and disease. This review provides an overview of pulmonary lymphatic biology and delves into the involvement of lymphatics in four major lung diseases: chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), asthma, and lung transplant rejection. We examine how lymphatic abnormalities manifest in each of these conditions and investigate the mechanisms through which lymphatic remodeling and dysfunction contribute to disease progression. Furthermore, we explore the therapeutic potential of targeting the lymphatic system to ameliorate these debilitating respiratory conditions. Despite the current knowledge, several crucial questions remain unanswered, such as the spatial and temporal dynamics of lymphatic changes, the molecular crosstalk between lymphatics and the lung microenvironment, and the distinction between protective versus detrimental lymphatic phenotypes. Unraveling these mysteries holds the promise of identifying novel molecular regulators, characterizing lymphatic endothelial phenotypes, and uncovering bioactive mediators. By harnessing this knowledge, we can pave the way for the development of innovative disease-modifying therapies targeting the lymphatic highway in lung disorders.